CJC-1295 vs Ipamorelin
These two are not really rivals — they're studied together because they act through different receptors on the growth-hormone axis. Understanding the difference is the point: CJC-1295 is a GHRH analogue, Ipamorelin is a selective GH-releasing peptide.
two different receptors
CJC-1295 is a GHRH analogue — it mimics growth-hormone-releasing hormone to prompt the pituitary to release GH. Ipamorelin is a GH-releasing peptide (GHRP), a selective ghrelin-receptor agonist that amplifies release through a separate receptor. Same axis, two different entry points.
why 'selective' matters for Ipamorelin
Among GHRPs, ipamorelin is the one studied for a selective profile — associated with GH release without the broader hormonal cross-talk of older GHRPs. That selectivity is why it's the GHRP of choice when it's paired with a GHRH analogue.
why they're paired, not chosen between
Because the two mechanisms are complementary, the research interest is in running them together — the reasoning behind the single CJC-1295 + Ipamorelin pen. If you want the GHRH arm on its own, tesamorelin isolates it.
verifying the blend
Because the pen supplies both compounds, the certificate of analysis should confirm the identity and proportion of each — see how to read a CoA. More on the class in the growth & recovery range.
research use only
Both compounds are supplied strictly for in-vitro and laboratory research use only — not medicines, not for human or veterinary consumption. Nothing here is dosing, medical or treatment guidance.
the research pens
Pre-filled, batch-numbered and independently assayed. Save one to your list and we'll email you the moment it's available in your country.
Overview
CJC-1295 and Ipamorelin are distinct research materials: CJC-1295 is a GHRH analogue that targets the pituitary GHRH receptor, while Ipamorelin is a growth-hormone secretagogue that acts at GHS-R (the ghrelin receptor). Because the two compounds enter the growth-hormone axis at different receptor classes, each engages its own receptor pathway in an in-vitro assay. A paired research format suits a protocol that requires both receptor pathways to be engaged simultaneously.
A second identity issue compounds the comparison: the label “CJC-1295” does not describe a single molecular entity. In the originating pharmacology literature, CJC-1295 denotes a DAC (Drug Affinity Complex) albumin-binding conjugate of modified GHRH(1–29). Merchant catalogues frequently apply the same name to the peptide without that albumin-binding group, sometimes calling it “CJC-1295 no DAC” or aligning it with modified GRF(1–29). These are materially different structures with different exact masses and different pharmacokinetic profiles in the original reports. The exact format is confirmed against the certificate of analysis (CoA) for the batch in hand.
This comparison explains the receptor distinction between CJC-1295 and Ipamorelin, shows why DAC and non-DAC CJC-1295 are separated, and sets out the batch documentation to check before procurement. To confirm current commercial terms or submit a purchase enquiry, use the checkout or enquiry path on the relevant Veyvora product page. All materials and discussion on this page are for laboratory and in-vitro research use.
CJC-1295 vs Ipamorelin: The Short Verdict
CJC-1295 is a GHRH analogue that targets the pituitary GHRH receptor, while Ipamorelin is a selective GHRP that acts at GHS-R, the ghrelin receptor. Each compound enters the growth-hormone axis at a distinct receptor class, making the compounds mechanistically complementary research ligands. Selecting between them depends on the assay question, the exact material identity confirmed by the certificate of analysis, and the quality of batch documentation.
A protocol investigating GHRH-receptor signalling requires a confirmed GHRH analogue; a protocol investigating GHS-R requires a confirmed GH-releasing peptide agonist such as Ipamorelin. Veyvora (2026) states that each batch is tested by Asterion Analytics, then again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin assay, with assay purity reported at ≥98.0%, documentation that supports receptor-class verification before work begins. For a deeper explanation of why both pathway inputs may be studied in parallel, see the CJC-1295 + Ipamorelin research explainer.
Key Takeaways
- CJC-1295 engages GHRHR; Ipamorelin engages GHS-R, so the two materials answer different receptor questions.
- DAC and non-DAC CJC-1295 have different structures, masses and albumin-binding characteristics, so the CoA states the format clearly.
- A defensible batch record includes mass-spectrometry identity, HPLC purity, peptide-content data, endotoxin data where relevant, and a matching batch number.
- A paired format suits an assay designed to examine both receptor pathways independently.
What Is a GH-Releasing Peptide?
A GH-releasing peptide (GHRP) is a synthetic oligopeptide studied for its activity as a growth-hormone secretagogue, a compound that stimulates growth-hormone release through receptor-mediated pathways. In strict pharmacological usage, the term GHRP refers specifically to agonists of GHS-R (the ghrelin receptor), a receptor class distinct from the pituitary GHRH receptor targeted by GHRH analogues such as CJC-1295. Research catalogues sometimes apply the phrase loosely to any GH-axis peptide; laboratory methods writing keeps the two receptor classes distinct.
| Compound class | Primary receptor | Representative research ligand |
|---|---|---|
| GHRH analogue | Pituitary GHRH receptor (GHRHR) | CJC-1295 |
| GH-releasing peptide (GHRP) | Ghrelin receptor (GHS-R / GHSR-1a) | Ipamorelin |
The distinction matters for assay design: a protocol targeting GHRHR signalling requires a confirmed GHRH analogue, while a protocol targeting GHS-R requires a confirmed GHRP agonist. GHRP is a mechanism label derived from primary pharmacology literature. Before accepting any material into a GH-axis assay, verify a batch against its certificate of analysis to confirm which receptor class the supplied sequence is designed to engage. The storage and stability guidance for research peptides covers handling before use.
CJC-1295 Is a GHRH Analogue
CJC-1295 is classified as a GHRH analogue because its peptide backbone is a chemically modified fragment of human growth hormone-releasing hormone, specifically a tetrasubstituted GHRH(1–29) sequence designed to retain agonism at the pituitary GHRH receptor (GHRHR). That receptor-class designation is independent of whether the albumin-binding Drug Affinity Complex (DAC) moiety is present or absent.
DAC Versus Non-DAC: A Material Identity Issue
In the originating pharmacology literature, CJC-1295 names the DAC-bearing conjugate, in which a maleimidopropionyl group enables covalent binding to circulating albumin. Merchant catalogues have since applied the label “CJC-1295 without DAC” or “CJC-1295 no DAC” to the tetrasubstituted GHRH(1–29) peptide stripped of that moiety, a sequence more precisely aligned with modified GRF(1–29). The two formats share receptor-class intent but differ in molecular mass, covalent albumin-binding capacity and exact structure, and are named separately in methods writing and batch ordering.
The certificate of analysis states which format has been supplied; consult it before any material enters a GHRHR assay. A minimum specification checklist for batch acceptance covers:
- Compound name as stated on the CoA
- Sequence or structural format where disclosed (DAC or non-DAC)
- DAC status confirmed against molecular-mass result
- Batch number matched to the CoA
- Molecular-mass result from mass spectrometry
- HPLC chromatographic purity result
- Endotoxin result where the assay system is endotoxin-sensitive
HPLC area-percent reports chromatographic purity; mass spectrometry provides the orthogonal identity check [1]. Researchers working across the GHRH-analogue class may also find the tesamorelin as a GHRH analogue reference page useful for a mechanistic comparator, and the Growth & Recovery research catalogue provides a focused route to available GHRHR-targeted materials.
Ipamorelin Is a Selective GHRP
A selective GH-releasing peptide (selective GHRP) is a synthetic oligopeptide agonist of the ghrelin receptor (GHS-R, specifically the GHSR-1a subtype) that stimulates GH secretion with comparatively limited activity at other pituitary axes. Ipamorelin is classified within this ligand class on the basis of early pharmacology work, specifically Raun et al., European Journal of Endocrinology, 1998. That study reported GH secretagogue activity at GHS-R with less concomitant ACTH/cortisol and prolactin signal than GHRP-6 in the experimental systems examined, and described ipamorelin as the first selective growth-hormone secretagogue. That characterisation is a receptor-class and relative-selectivity descriptor for those specific assay conditions.
What Selectivity Means for Laboratory Work
Selectivity, as used in the GHRP literature, describes a ligand’s relative preference for GHS-R over other pituitary receptors in a defined experimental system. Purity, sequence identity and endotoxin status of a particular batch are reported on its CoA. Material labelled “ipamorelin” is confirmed by orthogonal mass spectrometry alongside its HPLC purity before GHS-R activity in an assay is attributed to it; see what HPLC purity does and does not prove for how area-percent data is read [1].
Ipamorelin acts through GHS-R, whereas CJC-1295 targets the GHRH receptor (GHRHR). Each addresses its own receptor in a GHRHR or GHS-R assay, and the two compounds are mechanistically complementary. The CJC-1295 + Ipamorelin research explainer covers the rationale for studying both receptor inputs in parallel.
CJC-1295 vs Ipamorelin Comparison Table
CJC-1295 and Ipamorelin are mechanistically complementary research peptides: CJC-1295 is a GHRH analogue acting at the GHRH receptor (GHRHR), while Ipamorelin is a selective GHRP acting at the ghrelin receptor (GHS-R), placing the two compounds at distinct entry points on the growth-hormone axis.
| Criterion | CJC-1295 (DAC form) | CJC-1295 (non-DAC / modified GRF 1–29) | Ipamorelin |
|---|---|---|---|
| Peptide class | GHRH analogue | GHRH analogue | Selective GHRP |
| Principal receptor / pathway | GHRHR | GHRHR | GHS-R (GHSR-1a) |
| Defining structural feature | Tetrasubstituted GHRH(1–29) + albumin-binding DAC moiety | Tetrasubstituted GHRH(1–29); no DAC | Pentapeptide GH secretagogue |
| Format naming | DAC conjugate is the literature entity | ”CJC-1295 no DAC” is market terminology for modified GRF(1–29) | Single well-described sequence |
| Selectivity terminology | GHRHR agonist; the “selective GHRP” descriptor belongs to the GHS-R class | GHRHR agonist | Described as the first selective growth-hormone secretagogue (Raun et al., 1998; assay-dependent) |
| Evidence maturity | Primary pharmacology papers from 2005–2006; no 2024–2026 peer-reviewed update identified | Shares receptor class with DAC form; independent evidence base is smaller | Primary in-vitro and animal data from 1998; no 2024–2026 peer-reviewed update identified |
| Identity confirmation | Exact mass and covalent albumin-binding group matched to the CoA | Sequence and mass confirmed against the certificate of analysis, since the name overlaps with the DAC form in catalogues | Short, well-characterised sequence; mass-spectrometry confirmation on the CoA |
| Suitable in-vitro question | GHRHR binding, receptor activation, GHRHR-pathway assays | GHRHR-pathway assays where DAC albumin-binding is not required | GHS-R binding, receptor activation, GHS-R-pathway assays |
| Minimum documentation required | CoA with HPLC purity, mass-spectrometry identity, endotoxin result, batch number | CoA with HPLC purity, mass-spectrometry identity, endotoxin result, batch number; sequence stated explicitly | CoA with HPLC purity, mass-spectrometry identity, endotoxin result, batch number |
Reading the Table Correctly
Receptor classification is a literature descriptor for a defined molecular entity; identity testing on the specific vial in hand sits alongside it. Before accepting any batch, verify the batch number against its certificate of analysis and confirm that the stated sequence, molecular mass and purity meet your protocol’s acceptance criteria. For cold-chain requirements that affect material integrity before the CoA is even consulted, see storage and stability guidance for research peptides.
When Does a Paired Format Make Sense?
A paired CJC-1295 and Ipamorelin format suits a research protocol that is designed to examine activity across both the GHRH-receptor (GHRHR) pathway and the ghrelin-receptor (GHS-R) pathway simultaneously, with each compound’s identity independently confirmed against its own certificate of analysis before the experiment begins.
Decision Rules for Protocol Design
The choice of format follows the receptor question:
- GHRHR pathway in isolation: use CJC-1295 (DAC or non-DAC, specified precisely) as the sole ligand. For a well-characterised GHRH-analogue comparator with a distinct structural profile, the tesamorelin research page provides a useful reference point.
- GHS-R pathway in isolation: use Ipamorelin as the sole ligand. Adding a GHRHR agonist alongside Ipamorelin introduces a second mechanistic input, so attribution of any observed signal needs separate controls.
- Combined pathway activity: a paired format is appropriate when the assay system, for example primary pituitary cultures expressing both GHRHR and GHS-R, requires stimulation of both receptors as independent variables. The protocol states which receptor each compound addresses, treating each as its own variable.
Mechanistic complementarity describes two separate inputs; combined outcomes are what a dual-pathway assay measures. Researchers designing dual-pathway assays can find a deeper mechanism discussion in Veyvora’s CJC-1295 and Ipamorelin research explainer.
The Verification Matrix
A research choice rests on material that can be independently verified. The table below sets out the criteria that determine whether a batch of CJC-1295 or Ipamorelin is fit for reproducible in-vitro work.
| Verification criterion | What to require | What each line adds |
|---|---|---|
| Molecular identity | Mass spectrometry confirming the correct molecular mass for the stated format (DAC or non-DAC for CJC-1295; pentapeptide mass for Ipamorelin) | HPLC area-percent reports chromatographic purity relative to observed peaks; mass spectrometry confirms the molecular mass of the stated sequence [1] |
| Chromatographic purity | Batch-specific HPLC result with stated threshold | Purity is relative to detected peaks; non-chromophoric counter-ions and water content are reported by separate methods [1] |
| Peptide content / concentration | Separate quantitative assay (e.g. amino-acid analysis or calibrated content method) | Concentration is a separate figure from HPLC purity [1] |
| Endotoxin | LAL or equivalent result, particularly where the assay system is endotoxin-sensitive | Endotoxin is a distinct test with its own line [1] |
| Independent laboratory testing | Results from at least two separate laboratories per batch | Two laboratories’ results check each other for systematic error or instrument bias |
| Batch-number traceability | CoA batch number matches the pen label and dispatch documentation | The batch number ties the CoA to the material received |
| Synthesis-partner disclosure | Supplier identifies the synthesis partner where disclosure is permitted | Reseller identity and manufacturer identity are distinct; disclosure shows the supply chain |
| Cold-chain evidence | Dispatch under documented cold-chain conditions in an insulated bag with a gel ice pack | A physical temperature record documents transit conditions |
How Veyvora’s Stated Controls Map to This Matrix
Veyvora’s batch documentation (2026) states that each batch is tested by Asterion Analytics, then again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin assay, with an assay-purity threshold of ≥98.0%. Orders are stated to be dispatched within 24 hours under documented cold-chain conditions in an insulated bag with a gel ice pack. Every pen ships with an independent, batch-specific certificate of analysis, with the batch number matched to that certificate at the point of dispatch. Veyvora also discloses synthesis-partner detail for a batch where the supply agreement permits, so its stated controls map across the verification matrix above.
ICH Q6B frames identity, purity and quantity as separate specification elements [1]; a complete CoA reports all three. Veyvora’s CJC-1295 + Ipamorelin research explainer covers the dual-pathway rationale in more depth, and the dedicated page on what HPLC purity does and does not prove resolves the next practical question once a CoA is in hand.
Research Use
CJC-1295, Ipamorelin and all related GH-axis research peptides from Veyvora are supplied for in-vitro laboratory research: receptor-binding and signalling assays, cell-culture work and analytical reference. Not for human or veterinary use.
Pre-Order Checklist for Buyers and Distributors
Before placing an order, confirm each of the following:
- Intended application is documented as in-vitro laboratory research
- Institutional ethics or biosafety controls are in place and recorded
- A hazardous chemical agent risk assessment under the Regulations for Hazardous Chemical Agents, 2021 (made under the Occupational Health and Safety Act 85 of 1993) is completed for the specific peptide
- Local import classification and any required permits have been verified for the destination country
- Resale or redistribution terms follow the jurisdiction’s requirements for research materials
- Batch documentation, including the certificate of analysis, is retained for audit purposes
- Downstream communication describes the material as a research compound
Once material is received, verify a batch against its certificate of analysis before use, and consult storage and stability guidance for research peptides to confirm cold-chain conditions are maintained from receipt onwards.
Current Price, Availability and Purchase Route
Current price, stock and eligible delivery markets for the CJC-1295 + Ipamorelin research pen are shown on Veyvora’s live product and checkout pages; take commercial terms from there rather than from this article. Veyvora states that research-peptide orders are dispatched within 24 hours under documented cold-chain conditions in an insulated bag with a gel ice pack.
For laboratories selecting a research domain, the Growth & Recovery research catalogue provides a focused route to relevant products. Researchers requiring a GHRH-only comparator for protocol design may find the tesamorelin as a GHRH analogue page useful before finalising material selection.
To view current availability, pricing and the approved purchase or wholesale enquiry route, visit the relevant product page on Veyvora’s site.
Questions Laboratories Should Resolve Before Ordering
Before selecting CJC-1295, Ipamorelin or a paired format, a laboratory confirms molecular identity, batch documentation, import requirements and cold-chain integrity. The answers below address the questions most likely to affect protocol reproducibility and procurement decisions.
Are CJC-1295 and Ipamorelin the Same Type of Peptide?
No. CJC-1295 is a GHRH-receptor agonist analogue; Ipamorelin is a GHS-R agonist. They act through different receptors on the growth-hormone axis and are mechanistically complementary; each addresses its own receptor in an in-vitro assay.
What Is a GHRH Analogue?
A GHRH analogue is a synthetic peptide designed to activate the pituitary GHRH receptor (GHRHR), mimicking the action of endogenous growth-hormone-releasing hormone. CJC-1295 is a tetrasubstituted analogue of human GHRH(1–29); the DAC-bearing version additionally binds circulating albumin to extend exposure in experimental systems.
What Is a Selective GHRP?
A GH-releasing peptide (GHRP) is a synthetic oligopeptide agonist of the ghrelin receptor (GHS-R). Ipamorelin is described in the primary literature as a selective GHRP because early experimental data indicated GH secretagogue activity at GHS-R with comparatively less stimulation of ACTH/cortisol and prolactin than earlier GHRPs. Selectivity is assay- and species-dependent.
Does CJC-1295 DAC Differ From Non-DAC Material?
Yes, materially. In the primary pharmacology literature, CJC-1295 denotes the albumin-binding DAC conjugate of modified GHRH(1–29). Merchant catalogues have also labelled tetrasubstituted GHRH(1–29) without the DAC moiety as “CJC-1295 no DAC.” These are structurally distinct materials; confirm the exact format against the certificate of analysis before use.
Does HPLC Alone Prove Identity?
HPLC area-percent reports chromatographic purity relative to observed peaks; amino-acid sequence, absolute peptide content and endotoxin status are reported by their own methods [1]. Identity comes from orthogonal confirmation, at minimum mass spectrometry. The what HPLC purity does and does not prove page sets out what the method reports.
What Evidence Should a Laboratory Require Before Accepting a Batch?
Require a batch-specific certificate of analysis covering: mass-spectrometry identity, HPLC chromatographic purity, a separate peptide-content or amino-acid-analysis result, stated sequence and counter-ion, and a bacterial endotoxin result when the in-vitro system is endotoxin-sensitive [1]. The batch number on the pen label matches the CoA exactly.
What Does Research Use Only Mean?
Research use means the material is supplied for in-vitro laboratory work: receptor-binding and signalling assays, cell-culture work and analytical reference. The research-use designation appears on the batch documentation, and the pre-order checklist above covers the import and redistribution points a distributor confirms for its own territory.
For a deeper explanation of why the two receptor pathways may be studied in parallel, the CJC-1295 + Ipamorelin research explainer provides the mechanistic context. To confirm current availability and the approved purchase route, visit the relevant product page on Veyvora’s site directly.
Sources
[1] ICH Q6B specification principles (analytical review), pmc.ncbi.nlm.nih.gov, https://pmc.ncbi.nlm.nih.gov/articles/PMC5830484/
